Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Société

InterAx Biotech SA

InterAx Biotech SA_logo
27
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

We are pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health.

Villigen, Aargau, Suisse

Envoyer un message

Français

Français

Anglais

InterAx Biotech SA
Français

Français

Anglais

InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). It has developed a unique drug discovery platform to reduce the time and costs for discovery and development of new drugs for a wide array of human diseases. InterAx technology combines in-vitro cell signaling experiments with mathematical modeling of signaling pathways and machine learning to discover new...

En savoir plus

InterAx Biotech AG is a research-based Swiss company, spin-off from the ETH Zürich and the Paul Scherrer Institute (PSI). It has developed a unique drug discovery platform to reduce the time and costs for discovery and development of new drugs for a wide array of human diseases. InterAx technology combines in-vitro cell signaling experiments with mathematical modeling of signaling pathways and machine learning to discover new effective treatments and de-risk clinical trials.

Partnerships with leading pharmaceutical companies, Boehringer Ingelheim and Lundbeck, and South Korean biotech company, GPCR Therapeutics, allowed us to validate the technology platform. InterAx is currently applying its technology to an in-house drug discovery program in the field of oncology and has discovered a new molecular entity targeting solid tumours in several cancer subtypes with high unmet needs.

Membre(s) de l'équipe

Votre demande a bien été adressée
Rejoindre cette organisation
Your request has been sent

Notre réseau

Votre demande a bien été envoyée
Rejoindre ce réseau
Votre message a bien été envoyé

Labels

EUREKA Accelerated
215 Organisations

Communautés

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Membres
Access2EIC
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2140 Membres
TAFTIE High Potential
TAFTIE is the European Network of Innovation Agencies. 11 agencies: Tekes, Hamag-Bicro, TA CR, ENEA, CDTI, ANI, Luxinnovation, Bpifrance, RVO.nl, Enterprise Estonia, Innovate UK decided to launch the TAFTIE High Potential Community. This community aims at gathering the best high potential innovative SMEs with European ambition belonging to these agencies' network. Our goal is to provide them more visibility and a better access to new business opportunities such as European investors.
194 Membres